Article

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

2020-11-29

Abstract excerpt

<h4>Summary</h4> Resistance to endocrine therapies (ET) is common in estrogen receptor (ER) positive breast cancer and most relapsed patients die with ET-resistant disease. While genetic mutations provide explanations for some relapsed patients 1 , mechanisms of resistance remain undefined in many cases. Drug-induced epigenetic reprogramming provides possible routes to resistance 2 . By analysing histone H3 lys...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5adab234-230c-5a2c-a01e-0f6642a2df08
DOI: 10.1101/2020.11.29.402842

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

VGLL1 drives therapy resistance in estrogen receptor positive breast cancerDOI 10.1101/2020.11.29.402842Read

Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast CancerSemantic proximity Read

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancerSemantic proximity Read

PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine ResistanceSemantic proximity Read

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast CancerSemantic proximity Read

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read

ERα-LBD, a novel isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistanceSemantic proximity Read

ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.Semantic proximity Read

Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast CancerSemantic proximity Read

FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.Semantic proximity Read

Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complexSemantic proximity Read

The impact of Fulvestrant on Estrogen Receptor-Driven Chromatin Dynamics in Breast CancerSemantic proximity Read

Estrogen deprivation triggers an immunosuppressive phenotype in breast cancer cellsSemantic proximity Read